

TILDELING AV FORSKNINGSMIDLER OPEN CALL 2016



| Prosjektleder | Søknadstittel | Institusjon | Beløp |
|----------------------|--|--|-----------|
| Hilde Nilsen | Genome instability and inflammation in early stages of cancer development | Akershus universitetssykehus HF | 5 000 000 |
| Anne Ree | Shaping antitumor immunity in advanced colorectal cancer | Akershus universitetssykehus HF | 8 000 000 |
| Randi Elin Gislefoss | Impact of Vitamin D, obesity, and bladder cancer: risk and prognosis | Kreftregisteret | 2 248 000 |
| Bo Terving Hansen | Equalscreen: Increasing participation and reducing inequities in cervical cancer screening | Kreftregisteret | 3 500 000 |
| Bjørn Møller | Evaluation of cancer patient pathways in Norway | Kreftregisteret | 3 200 000 |
| Ameli Trope | Incremental improvement of cervical cancer screening: The balance of benefits and harms | Kreftregisteret | 3 600 000 |
| Xiao-Mei Mai | Repeated measures of genome-wide DNA methylation as early detection markers and mediators for non-small-cell lung cancer | Norges teknisk-naturvitenskapelige universitet | 3 500 000 |
| Valentyn Oksenysh | Function of non-homologous DNA End joining factors PAXX and DNA-PKcs in protection from medulloblastoma tumor | Norges teknisk-naturvitenskapelige universitet | 3 799 824 |
| Signe Opdahl | Risk of hormone-related cancer in women following assisted reproductive technology | Norges teknisk-naturvitenskapelige universitet | 1 572 000 |
| Menno Oudhoff | Methylation turnover tunes WNT-driven intestinal tumorigenesis via the hippo transducer YAP | Norges teknisk-naturvitenskapelige universitet | 6 500 000 |
| Svein Dueland | Liver transplantation in selected patients with colorectal cancer liver metastases | Oslo universitetssykehus - Radiumhospitalet | 4 700 000 |
| Jon Amund Kyte | Immunotherapy with retargeted T cells against solid cancers | Oslo universitetssykehus - Radiumhospitalet | 7 500 000 |
| Heidi Lyng | Molecular biomarkers in radiotherapy of cancer | Oslo universitetssykehus - Radiumhospitalet | 8 600 000 |
| Eirik Malinen | Bioradiance | Oslo universitetssykehus - Radiumhospitalet | 4 282 000 |
| Johanna Olweus | Outsourcing cancer-specific immunity to healthy donors | Oslo universitetssykehus - Radiumhospitalet | 7 500 000 |
| Mouldy Sioud | Turn peptides and single chain Fv antibodies into effective cancer cell killers | Oslo universitetssykehus - Radiumhospitalet | 5 000 000 |

| Prosjektleder | Søknadstittel | Institusjon | Beløp |
|--------------------------|--|---|-----------|
| Erlend Bremertun Smeland | Precision medicine in B-cell lymphoma | Oslo universitetssykehus - Radiumhospitalet | 7 754 000 |
| Harald Stenmark | Dysregulated cell division and its implications for cancer | Oslo universitetssykehus - Radiumhospitalet | 7 500 000 |
| Bjørn Atle Bjørnbeth | Acetylsalicylic acid as secondary prevention in colorectal cancer (ASAC trial) | Oslo universitetssykehus - Rikshospitalet | 5 954 000 |
| Magnar Bjørås | Oxidative stress induced DNA base modifications in cancer: Novel biomarkers and drug targets | Oslo universitetssykehus - Rikshospitalet | 6 000 000 |
| Alexandre Corthay | Cancer immunotherapy by optimized activation of tumor-associated macrophages | Oslo universitetssykehus - Rikshospitalet | 5 000 000 |
| Jorrit Enserink | Development of novel treatment for acute myeloid leukemia | Oslo universitetssykehus - Rikshospitalet | 7 500 000 |
| Rolf Bjerkvig | Targeting the invasive tumor cells in malignant brain tumors | Universitetet i Bergen | 5 151 551 |
| Tone Bjørge | Long-term adverse health effects in cancer patients: Prescribing of drugs in survivors of adult-onset cancer | Universitetet i Bergen | 2 576 000 |
| Øystein Bruserud | New pharmacotherapy for acute myeloid leukemia: the chemokine system and its biological context | Universitetet i Bergen | 4 811 200 |
| Nils Halberg | Malignant exploitation of obesity-linked inflammation | Universitetet i Bergen | 5 000 000 |
| Emmet Mc Cormack | Novel models and therapeutic options for haematological malignancies | Universitetet i Bergen | 7 500 000 |
| Frits Thorsen | Finding new uses for old drugs in clinical treatment of brain metastases | Universitetet i Bergen | 4 759 254 |
| Bjarne Bogen | Patient-specific cancer vaccines delivered with targeted DNA | Universitetet i Oslo | 5 000 000 |
| Hesso Farhan | Spatial Cdc42 signaling at the golgi and the regulation of cancer cell migration and invasion | Universitetet i Oslo | 6 000 000 |
| Fahri Saatcioglu | Androgen action and prostate cancer: Identification of biomarkers and therapeutic targets | Universitetet i Oslo | 7 500 000 |
| Kjetil Taskén | Targeting tumor immune evasion mechanisms mediated by prostaglandin E2, cyclic AMP and regulatory T cells | Universitetet i Oslo | 6 000 000 |
| Tom Dønnem | Clinical implementation of TNM-Immunoscore in resected non-small cell lung cancer | Universitetet i Tromsø | 2 650 000 |
| Torkjel Sandanger | Identifying biomarkers for metastatic lung cancer: An investigation of subtle alterations in gene expression, DNA methylation and MIRNA in blood prior to clinical diagnosis (Id-Lung) | Universitetet i Tromsø | 4 000 000 |